{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T17:56:10Z","timestamp":1767117370656,"version":"3.41.0"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Noninvasive prenatal screening for common autosomal trisomies, sex chromosome aneuploidies and microdeletions vary by methodology and laboratory practice. The fetal portion of all cell-free DNA in the maternal circulation defines the fetal fraction (FF). The minimum specimen FF levels for reporting results vary between laboratories as well as the screening target (e.g., common trisomies vs select microdeletions). This variability can lead to confusion for both healthcare providers and patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Participants in the College of American Pathologists Non-Invasive Prenatal Testing 2021-B Exercise provided FF estimates for 3 manufactured samples. Responses to supplemental questions were also collected and analyzed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Overall, 72 of 77 participants responded. FF was measured by 66 participants using sequence counts (40), single nucleotide polymorphisms (15), fragment length (24), and Y chromosome sequences (24). Nearly half (48%) used multiple methods. For common trisomies, minimum FFs were none or &amp;lt;1% (n = 7), 1.0% to 3.9% (n = 35), 4.0% to 6.9% (n = 23), and \u22657.0% (n = 1); 4 participants did not measure FF. Challenge-specific FFs were variable with CVs of 13%, 15%, and 36%; the latter rate appears due to that sample\u2019s fetal karyotype of 47,XYY. Comparing adjusted FF results for the 3 samples shows that 85% of participant results were within 20% of the consensus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Using multiple methods to estimate FF was common, and cutoff levels for sample suitability varied widely. Within-laboratory FFs were less variable than between laboratories. Current FF estimates from clinical laboratories are not standardized and should be considered laboratory-specific.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jalm\/jfaf062","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T09:45:01Z","timestamp":1747388701000},"page":"852-862","source":"Crossref","is-referenced-by-count":1,"title":["Fetal Fraction Methodologies and Their Clinical Use: Results of a College of American Pathologists Exercise"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6154-8449","authenticated-orcid":false,"given":"Glenn E","family":"Palomaki","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Alpert Medical School at Brown University, Women & Infants Hospital of Rhode Island , Providence, RI ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Wyatt","sequence":"additional","affiliation":[{"name":"Esoterix Genetic Laboratories , Santa Fe, NM ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ross A","family":"Rowsey","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Phillip Michael","family":"Cacheris","sequence":"additional","affiliation":[{"name":"Sequenom Laboratories , San Diego, CA ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Lepage","sequence":"additional","affiliation":[{"name":"Newborn Screening Ontario, Children\u2019s Hospital of Eastern Ontario , Ottawa, ON ,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marvin R","family":"Natowicz","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Medicine, Genomic Medicine, Neurology and Pediatrics Institutes, Cleveland Clinic , Cleveland, OH ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Long","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, College of American Pathologists , Northfield, IL ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2590-7218","authenticated-orcid":false,"given":"Ann M","family":"Moyer","sequence":"additional","affiliation":[{"name":"Division of Laboratory Genetics and Genomics, Department of Laboratory Medicine and Pathology, Mayo Clinic , Rochester, MN ,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"key":"2025070109062514000_jfaf062-B1","doi-asserted-by":"crossref","first-page":"1066178","DOI":"10.3389\/fped.2023.1066178","article-title":"Maternal and fetal factors influencing fetal fraction: a retrospective analysis of 153,306 pregnant women undergoing noninvasive prenatal screening","volume":"11","author":"Deng","year":"2023","journal-title":"Front Pediatr"},{"key":"2025070109062514000_jfaf062-B2","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1373\/clinchem.2018.288670","article-title":"Specifying a gold standard for the validation of fetal fraction estimation in prenatal screening","volume":"64","author":"Wald","year":"2018","journal-title":"Clin Chem"},{"key":"2025070109062514000_jfaf062-B3","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/uog.14694","article-title":"A unified approach to risk assessment for fetal aneuploidies","volume":"45","author":"Wright","year":"2015","journal-title":"Ultrasound Obstet Gynecol"},{"key":"2025070109062514000_jfaf062-B4","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1038\/gim.2018.22","article-title":"Prenatal cell-free DNA screening test failures: a systematic review of failure rates, risks of Down syndrome, and impact of repeat testing","volume":"20","author":"Palomaki","year":"2018","journal-title":"Genet Med"},{"key":"2025070109062514000_jfaf062-B5","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1002\/pd.5620","article-title":"Fetal fraction and noninvasive prenatal testing: what clinicians need to know","volume":"40","author":"Hui","year":"2020","journal-title":"Prenat Diagn"},{"key":"2025070109062514000_jfaf062-B6","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1177\/09691413211031610","article-title":"Prenatal serum screening for Down syndrome and neural tube defects in the United States: changes in utilization patterns from 2012 to 2020","volume":"28","author":"Lepage","year":"2021","journal-title":"J Med Screen"},{"key":"2025070109062514000_jfaf062-B7","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1097\/GIM.0b013e3182368a0e","article-title":"DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study","volume":"13","author":"Palomaki","year":"2011","journal-title":"Genet Med"},{"key":"2025070109062514000_jfaf062-B8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/gim.2011.73","article-title":"DNA sequencing of maternal plasma reliably identifies trisomy 18 and trisomy 13 as well as Down syndrome: an international collaborative study","volume":"14","author":"Palomaki","year":"2012","journal-title":"Genet Med"},{"key":"2025070109062514000_jfaf062-B9","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1002\/mgg3.1653","article-title":"Total number of reads affects the accuracy of fetal fraction estimates in NIPT","volume":"9","author":"Miceikait\u0117","year":"2021","journal-title":"Mol Genet Genomic Med"},{"key":"2025070109062514000_jfaf062-B10","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/s41436-020-01009-5","article-title":"High-throughput fetal fraction amplification increases analytical performance of noninvasive prenatal screening","volume":"23","author":"Welker","year":"2021","journal-title":"Genet Med"},{"key":"2025070109062514000_jfaf062-B11","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/clinchem\/hvac207","article-title":"Variability in fetal fraction estimation: comparing fetal fractions reported by noninvasive prenatal testing providers globally","volume":"69","author":"Becking","year":"2023","journal-title":"Clin Chem"},{"key":"2025070109062514000_jfaf062-B12","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1097\/AOG.0000000000004084","article-title":"Screening for fetal chromosomal abnormalities: ACOG Practice Bulletin, Number 226","volume":"136","author":"American College of Obstetricians and Gynecologists\u2019 Committee on Practice Bulletins\u2014Obstetrics","year":"2020","journal-title":"Obstet Gynecol"},{"key":"2025070109062514000_jfaf062-B13","doi-asserted-by":"crossref","first-page":"100336","DOI":"10.1016\/j.gim.2022.11.004","article-title":"Noninvasive prenatal screening (NIPS) for fetal chromosome abnormalities in a general-risk population: an evidence-based clinical guideline of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Dungan","year":"2023","journal-title":"Genet Med"},{"key":"2025070109062514000_jfaf062-B14","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1002\/pd.5918","article-title":"Not all low fetal fraction cell-free DNA screening failures are at increased risk for aneuploidy","volume":"41","author":"Caldwell","year":"2021","journal-title":"Prenat Diagn"}],"container-title":["The Journal of Applied Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/4\/852\/63204104\/jfaf062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jalm\/article-pdf\/10\/4\/852\/63204104\/jfaf062.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T13:06:33Z","timestamp":1751375193000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jalm\/article\/10\/4\/852\/8133595"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":14,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,5,16]]},"published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jalm\/jfaf062","relation":{},"ISSN":["2475-7241"],"issn-type":[{"type":"electronic","value":"2475-7241"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,5,16]]}}}